ELDN at a glance
Eledon Pharmaceuticals, Inc. (ELDN, SEC CIK 1404281) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Eledon Pharmaceuticals, Inc. (ELDN) shares worth $46.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $46.7M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly disclosed going-concern risk: $69.7 million liquidity does not fund operations for at least twelve months
- Clinical-development risk: Phase 3 kidney-transplant trial and islet-cell program require substantial additional financing
- Regulatory risk: 2025 Trump executive orders may alter FDA rules and delay approvals
- Manufacturing risk: no redundant supply arrangements for custom drug-production materials
- Competitive risk: Vertex and other larger companies developing immune-evasive islet-cell therapies
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or product sales
- Operating margin not meaningful, operating loss $21.7M vs $19.1M YoY
- R&D expenses $17.8M, up $2.8M YoY, driven by $5.1M higher manufacturing costs
- Cash, equivalents and short-term investments $69.7M, operating cash use $64.3M for nine months
- Phase 3 LEGACY planned for late 2026, additional financing required, substantial doubt about going concern
AI summary of the ELDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Eledon’s quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s quarterly financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 2026 revenue-free biotech posted a $21.0M operating loss excluding warrant revaluation, highlighting continued cash burn ahead of Phase 3
- Cash, equivalents and short-term investments $69.7M, funding operations into Q2 2027 but likely requiring additional financing afterward
Item EX-99.1: Item EX-99.1
- FDA alignment supports global Phase 3 kidney-transplant trial, targeting approximately 600 patients and initiation in late 2026
- BESTOW data showed eGFR approximately 12 mL/min/1.73 m² higher at 18 months versus tacrolimus, with p<0.05
Item 2.02: Results of Operations and Financial Condition
- Press release announces Eledon Pharmaceuticals’ results for quarter ended June 30, 2026
- Investors should review Exhibit 99.1 for financial results, operating updates and management commentary
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Stockholders approved a charter amendment at the June 18, 2026 Annual Meeting
- Amendment details are incomplete in the provided filing excerpt, limiting assessment of shareholder-rights impact
Item 5.07: Submission of Matters to a Vote of Security Holders
- Three Class III directors elected through 2029, preserving board continuity
- Authorized common shares increased 50%, from 300 million to 450 million
AI summaries of ELDN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ELDN
Don't miss the next ELDN filing
- Alerts as it files. A push when ELDN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ELDN, by share count.
- Ask anything. An AI agent that reads every ELDN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gros David-Alexandre C | A | Jul 31, 2026 | 354,454 | - |
| Gros David-Alexandre C | F | Jul 31, 2026 | 194,791 | $3.38 |
| Perrin Steven | A | Jul 31, 2026 | 152,353 | - |
| Perrin Steven | F | Jul 31, 2026 | 72,138 | $3.38 |
| Lee June | M | Jan 10, 2026 | 3,430 | - |
| Lee June | M | Jan 10, 2026 | 3,430 | - |
| Hillson Jan | M | Jan 10, 2026 | 3,430 | - |
| Hillson Jan | M | Jan 10, 2026 | 3,430 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$43.0M | - | - | |
| Net Income | -$40.3M | -$36.2M | -$45.6M | |
| Balance Sheet | ||||
| Total Assets | $89.1M | $177.4M | $169.0M | |
| Equity | $83.4M | $118.1M | $81.1M | |
| ROE | -48.3% | -30.6% | -56.3% | |
| Per Share | ||||
| EPS | $-1.64 | $-0.75 | $-0.52 | |
| Cash Flow | ||||
| Operating CF | -$39.5M | -$47.3M | -$62.3M | |
Source: XBRL data in Eledon Pharmaceuticals, Inc. (ELDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ELDN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $46.7M |
| Q2 2026 | 25 | $71.8M |
| Q1 2026 | 21 | $36.3M |
| Q4 2025 | 21 | $15.3M |
| Q3 2025 | 18 | $23.3M |
| Q2 2025 | 19 | $24.4M |
| Q1 2025 | 11 | $16.9M |
| Q4 2024 | 8 | $15.3M |
- BlackRock+1.52M (+30%)
- Renaissance Technologies LLC+356.0K (+177%)
- Goldman Sachs Group+51.0K (+2%)
- Raymond James Financial+40.8K (+115%)
- Northern Trust+14.4K (+2%)
- Bank of America Corp−575.6K (-65%)
- AQR Capital Management−504.8K (-87%)
- Morgan Stanley−234.2K (-48%)
- Millennium Management−189.9K (-19%)
- Citadel Advisors LLC−183.8K (-85%)
- StoneX Group Inc.+11.3K
- FMR LLC (Fidelity)−6.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ELDN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 10-K | Mar 19, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 16, 2026 | - | - | |
| 4 | Jan 16, 2026 | - | - | |
| 4 | Jan 16, 2026 | - | - | |
| 4 | Jan 16, 2026 | - | - | |
| 4 | Jan 16, 2026 | - | - | |
| 4 | Jan 16, 2026 | - | - | |
| 8-K | Jan 2, 2026 | - | - | |
| SC 13G | Nov 24, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 14, 2025 | Jun 30, 2025 | - | |
| SC 13G | Jul 29, 2025 | - | - | |
| SC 13G | Jul 17, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ELDN SEC filings: frequently asked questions
Which institutions hold ELDN stock?
As of September 30, 2026, the largest Eledon Pharmaceuticals, Inc. (ELDN) holders among the 13F filers tracked by SignalX were BlackRock ($16.8 million), Vanguard Capital Management LLC ($8.6 million), Goldman Sachs Group ($6.5 million), State Street Corp ($4.1 million), Millennium Management ($2.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ELDN report in its latest 8-K?
Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Eledon’s quarter ended September 30, 2026.
What are the latest ELDN SEC filings?
Eledon Pharmaceuticals, Inc. (ELDN) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 4, 2026.
What is ELDN's SEC CIK number?
Eledon Pharmaceuticals, Inc. (ELDN)'s SEC Central Index Key (CIK) is 1404281. EDGAR lists every ELDN filing under that number.
Ask anything about ELDN
The research agent reads ELDN's filings, financials, insider trades and 13F holders, then answers with sources.